title: The role of CETP inhibition in dyslipidemia.
abstract: Cholesteryl ester transfer protein (CETP) inhibitors are currently being investigated because of their ability to increase high-density lipoprotein cholesterol levels. In various metabolic settings, the relationship between CETP and lipoprotein metabolism is complex and may depend largely on the concentration of triglyceride-rich lipoproteins. Two CETP inhibitors, JTT-705 and torcetrapib, are in an advanced phase of development. Following hopeful intermediate results, a large endpoint study using torcetrapib has just been discontinued due to increased mortality in torcetrapib-treated subjects. In this review we summarize clinical data on the use of CETP inhibitors.
authors: Department of Vascular Medicine, Academic Medical Centre, University of Amsterdam, Room F4-159.2, Meibergdreef 9, Postbus 22660, 1105 AZ Amsterdam, The Netherlands. a.el-harchaoui@amc.uva.nl
authors: Karim
authors: K
authors: El Harchaoui
authors: Wim A
authors: WA
authors: van der Steeg
authors: Erik S G
authors: ES
authors: Stroes
authors: John J P
authors: JJ
authors: Kastelein
mesh_terms: D000577:Amides; D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors* / Q000502:physiology*; D002986:Clinical Trials as Topic; D050171:Dyslipidemias / Q000188:drug therapy*; D004952:Esters; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood; D015228:Hypertriglyceridemia / Q000097:blood; D008297:Male; D011804:Quinolines / Q000009:adverse effects / Q000627:therapeutic use; D013438:Sulfhydryl Compounds / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000577:Amides; D000924:Anticholesteremic Agents; C506642:CETP protein, human; D053480:Cholesterol Ester Transfer Proteins; D004952:Esters; D011804:Quinolines; D013438:Sulfhydryl Compounds; C411602:dalcetrapib; C483909:torcetrapib